Amarin (NASDAQ:AMRN) Announces Earnings Results, Beats Expectations By $1.28 EPS

Amarin (NASDAQ:AMRN) released its earnings results on Wednesday. The biopharmaceutical company reported $0.01 EPS for the quarter, topping the consensus estimate of ($1.27) by $1.28, FiscalAI reports. The firm had revenue of $49.22 million during the quarter, compared to analysts’ expectations of $50.62 million. Amarin had a negative net margin of 38.01% and a negative return on equity of 16.31%.

Here are the key takeaways from Amarin’s conference call:

• The company struck an exclusive long-term partnership with Recordati to commercialize VAZKEPA across 59 countries, delivering a $25 million upfront payment and up to $150 million in potential milestones while shifting European promotion and commercialization to Recordati to accelerate launches and scale.
• Amarin has materially cut costs from its global restructuring—realizing about half of the estimated $70 million in annualized savings by year-end, narrowing Q4 operating losses, generating positive operating cash flow in 2025, and finishing the year with $303 million in cash and no debt.
• In the U.S., VASCEPA retains market leadership and major managed-care exclusives, but Q4 U.S. revenue fell 7% due to lower net selling price and the company expects typical Q1 volume pressure, so near-term U.S. revenue remains sensitive to pricing and exclusivity dynamics.
• Amarin emphasizes a strong clinical evidence base—supporting 45 abstracts/papers in 2025 and recent REDUCE-IT analyses showing ~25% reduction in major cardiovascular events and fewer hospitalizations—using this data to differentiate VASCEPA versus therapies like fibrates and to support global commercialization.

Amarin Stock Down 11.7%

Shares of AMRN stock opened at $13.70 on Thursday. The stock has a market cap of $284.82 million, a price-to-earnings ratio of -5.55 and a beta of 0.84. Amarin has a fifty-two week low of $7.08 and a fifty-two week high of $20.90. The firm’s 50 day moving average price is $14.79 and its two-hundred day moving average price is $15.76.

Institutional Investors Weigh In On Amarin

A number of large investors have recently modified their holdings of AMRN. Two Sigma Investments LP lifted its position in Amarin by 1.8% during the 3rd quarter. Two Sigma Investments LP now owns 60,071 shares of the biopharmaceutical company’s stock worth $984,000 after acquiring an additional 1,047 shares in the last quarter. Sei Investments Co. lifted its position in shares of Amarin by 4.7% during the third quarter. Sei Investments Co. now owns 29,212 shares of the biopharmaceutical company’s stock worth $478,000 after purchasing an additional 1,299 shares in the last quarter. Banque Cantonale Vaudoise purchased a new position in shares of Amarin in the third quarter valued at $32,000. Ameriprise Financial Inc. grew its holdings in Amarin by 13.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 2,008 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Amarin by 34.8% during the 4th quarter. Wells Fargo & Company MN now owns 9,254 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 2,390 shares during the period. Institutional investors and hedge funds own 22.25% of the company’s stock.

Wall Street Analysts Forecast Growth

AMRN has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Amarin from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a report on Wednesday, January 21st. Finally, Zacks Research lowered shares of Amarin from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 27th. Three equities research analysts have rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Strong Sell” and a consensus target price of $12.00.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.